Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BCEL |
---|---|---|
09:32 ET | 560 | 0.0912 |
10:37 ET | 370 | 0.0914 |
10:39 ET | 1000 | 0.0935 |
10:51 ET | 150 | 0.092 |
11:13 ET | 5303 | 0.0923 |
11:29 ET | 7000 | 0.09365 |
11:38 ET | 130 | 0.09405 |
11:42 ET | 2500 | 0.09405 |
11:44 ET | 110 | 0.0931 |
01:08 ET | 1455 | 0.09405 |
01:26 ET | 4260 | 0.0931 |
01:33 ET | 1500 | 0.093765 |
01:39 ET | 1117 | 0.0931 |
02:24 ET | 200 | 0.09405 |
02:38 ET | 131 | 0.0931 |
03:30 ET | 112673 | 0.09 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Atreca Inc | 3.6M | 0.0x | --- |
Bio Path Holdings Inc | 3.6M | -0.1x | --- |
Avenue Therapeutics Inc | 3.5M | -0.1x | --- |
Clearmind Medicine Inc | 3.5M | -0.1x | --- |
Revelation Biosciences Inc | 3.6M | -0.1x | --- |
Novelstem International Corp | 3.5M | -0.8x | --- |
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $-2.49 |
Book Value | $2.01 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.